HMedical ResearchEIN: 473108868· Ruling Year: 2015

Treatments For Epilepsy And Symptoms Of Slc13 A5 Foundation

Menlo Park, California

B+Health Score
69B+

Financial Health Score

8-metric score across financial health, operational efficiency, and resilience. Based on IRS Form 990 filing data.

Good

💰
$504K
Total Revenue
📊
$498K
Total Expenses
🏦
$448K
Net Assets
📋
$12K
Total Liabilities

Financial Trends

5-Year Trend Analysis

Financial Health Indicators

Revenue Growth
-17.5%
Year-over-year change (2022 → 2023)
Net Margin
+1.2%
Revenue minus expenses as % of revenue
Working Capital Ratio
0.90
Net assets divided by total expenses
Liabilities-to-Assets
2.6%
Total liabilities as % of total assets

Filing History

9 filings on record
YearRevenueExpensesAssets
2023$503,64718%$497,68743%$459,7763%
2022$610,73460%$868,35186%$447,20738%
2021$381,26844%$466,822310%$717,89410%
2020$675,90172%$113,77969%$798,282257%
2019$392,66937%$368,510113%$223,54212%
2018$286,88954%$172,92330%$198,894134%
2017$185,76812%$248,656193%$84,92843%
2016$211,284406%$84,989321%$147,816587%
2015$41,725$20,204$21,521

Frequently Asked Questions

What does Treatments For Epilepsy And Symptoms Of Slc13 A5 Foundation do?

Treatments For Epilepsy And Symptoms Of Slc13 A5 Foundation is a medical research nonprofit organization based in California. It is classified under NTEE code H12 and is registered as a 501(c) tax-exempt organization with the IRS.

Is Treatments For Epilepsy And Symptoms Of Slc13 A5 Foundation financially healthy?

Financial health scoring requires Form 990 filing data. Check back as we process more filings for Treatments For Epilepsy And Symptoms Of Slc13 A5 Foundation.

How much revenue does Treatments For Epilepsy And Symptoms Of Slc13 A5 Foundation generate?

Treatments For Epilepsy And Symptoms Of Slc13 A5 Foundation reports $542K in annual revenue and holds $407K in total assets, based on IRS filings.

Similar Organizations

Explore more organizations in the Medical Research category, or browse all nonprofits in California.